Name: Latest research reports of Rossari Biotech Ltd. authored by ICICI Securities Limited and published by - Trendlyne research reports.
Item: Rossari Biotech Ltd.
Rating: 1
Author: ICICI Securities Limited

Performance acceleration may take some time

Sell: Rossari Biotech Ltd.

Recommendation Target

ICICI Securities Limited

Rossari Biotech’s (Rossari) Q1FY24 revenue dipped 5.5% YoY to Rs4.1bn due to drop in raw material prices, while volume grew ~20% YoY. Gross profit margin dipped 10bps QoQ despite softening raw material prices as the company focused on growing volumes and driving operating leverage. EBITDA margin has improved 70bps QoQ to 14.1%. Rossari expects revenue growth of 12-14% and EBITDA margin at 14% for FY24 despite a weak Q1FY24.